Jeff Lu is a company builder and investor working at the intersection of technology, AI and medicine across US and Asia (Singapore). He has built several biotech and tech companies, including Engine Bio (where he is currently CEO), Enleofen (acquired by Boehringer for >$1B), PairX, Bota Bio, GeneFab, AAE (acquired by Expedia), among others. He is also Founding Partner of NSG Ventures, a biotech VC firm.

Engine Bio is developing precision oncology therapeutics, leveraging its AI + biology platform and human data across geographies to generate translational insights on targets, biomarkers, and drugs. Under Jeff's leadership, Engine spun out from MIT, built and validated its platform, established its oncology pipeline, has raised $86M in funding from blue chip US and Asia investors, set up cross-border operations across SG and US, and secured several deals with industry, hospitals and academia.

Earlier in his career, Jeff led corporate and commercial strategy and data analytics at AirAsia and was a consultant at Bain & Company. He received his bachelor's degree from University of Pennsylvania (summa cum laude), and he is a member of YPO.